Search Results - antigens

10 Results

Sort By:

Antigens for preparation of monoclonal antibodies

Unmet NeedMonoclonal Antibodies (mAB) serve an important role in both research and medical applications to better understand components of biochemical pathways and the development of chronic diseases (Tabrizi et al, 2006[SN1] ). There is a global need for the advancement of antibodies to help target and fully understand the various, complex, molecular,...

Published: 6/13/2024 | Inventor(s): Gerald Hart

Keywords(s): Antigens, Basic Research Biomarker, Cell Signaling, Discovery/Research Tools, Research Reagent

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools

Targeted delivery of antigenic CTL peptide to tumor loci by Annexin V renders tumor cells susceptible to adaptive CD8+ cell immunity

Antigen-specific immunotherapy represents a promising methodology to control tumors because it can stimulate the immune system to specifically target and eliminate tumor cells. To overcome the challenge of immune tolerance, which is common to immunotherapy, we generated a novel chimeric protein to selectively coat tumor cells with a foreign immunogenic...

Published: 6/13/2024 | Inventor(s): Chien-Fu Hung, T.c. Wu

Keywords(s): Antigens, Biologics, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Intrinsic Activity of proPSA

A System to Enhance Understanding of the Intrinsic Activity of ProPSAJHU REF: [C12296]Invention novelty: This technology is a system to enhance understanding of the intrinsic proteolytic activity of ProPSA. Protein-specific antigen (PSA) is a protease secreted as a zymogen, ProPSA. Value Proposition: Variants of ProPSA are poorly understood. They...

Published: 6/13/2024 | Inventor(s): Simon Williams

Keywords(s): Antigens, Cell Signaling, Discovery/Research Tools, Research Reagent, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools

Autoimmunity-based Peptides as Cancer Vaccines

Autoimmunity-based Peptides as Cancer Vaccines JHU REF: C12807 Invention novelty: This technology uses autoantigen-derived peptides as novel immunotherapy to prevent and treat cancer. Value Proposition: Today, millions of people are living with cancer or have had cancer. Despite significant advances in cancer diagnosis and treatment over the...

Published: 6/13/2024 | Inventor(s): Erika Darrah, Christine Joseph, Kenneth Kinzler, Livia Casciola-Rosen, Nickolas Papadopoulos, Ami Shah, Antony Rosen, Bert Vogelstein

Keywords(s): Antigens, Biologics, Cancers, Disease Indication, Immunotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Vaccines

Bcl-2 BH4 domain-induced gene expression profiles

Bcl-2 BH4 domain-induced gene expression profilesJHU ID: C12295Abstract:Bcl-2 is a validated target for cancer therapies. Current small molecule drug inhibitors mimic the BH3 domain of pro-apoptotic Bcl-2 family members, binding to a pocket composed mainly of Bcl-2 homology (BH) domains 1-3, and only partially BH4. Surprisingly, while these agents are...

Published: 6/13/2024 | Inventor(s): Simon Williams

Keywords(s): Antigens, Basic Research Biomarker, Cancers, Cell Lines, Cell Signaling, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Prostate Cancer, Research Reagent, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools, Technology Classifications > Research Tools > Human Cell Lines, Clinical and Disease Specializations > Oncology > Prostate Cancer

PSMA-based Molecular-genetic Reporter System

PSMA-based Molecular-genetic Reporter SystemJHU REF: C12881Invention Novelty: A method of using the prostate-specific membrane antigen (PSMA) in combination with molecular reporting systems as an expression system to deliver the PSMA gene for diagnosis and imaging of prostate cancer.Value Proposition:PSMA is ideally suited to becoming a reporter because...

Published: 6/13/2024 | Inventor(s): Martin Pomper, Shawn Lupold, Mark Castanares, Il Minn

Keywords(s): Antigens, Basic Research Biomarker, Cancers, Cell Signaling, Discovery/Research Tools, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Positron Emission Tomography (PET), Research Reagent

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Medical Devices, Technology Classifications > Research Tools

Selectively Targeted Coating of Tumor Cells with Foreign Antigenic Peptide Renders Tumor Cells Susceptible to Antigen-specific CD8+ T Cell-mediated Killing

C11613: Novel Immunotherapy for Ovarian CancerNovelty: This invention is an immunotherapy that coats tumor cells with foreign antigenic peptide thereby rendering the coated tumor cells susceptible to immune recognition and elimination.Value Proposition: Cancer is the second most common cause of death in the industrialized world. Ovarian cancer is the...

Published: 6/13/2024 | Inventor(s): T.c. Wu, Chien-Fu Hung

Keywords(s): Antigens, Biologics, Cancers, Disease Indication, Immunotherapy, Ovarian Cancer, Peptide, Protein, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

PSMA-retargeted adenovirus

C11155: Method of developing targeted therapeutic agents for cancer using adenovirusValue Proposition: • Addresses a major patient need. • Specific for the target. • Enhances adenoviral gene therapy. • Has therapeutic and diagnostic applications. Technical Details: JHU scientists have developed a successful strategy to optimize targeted...

Published: 6/13/2024 | Inventor(s): Ping Wu, Ronald Rodriguez, Shawn Lupold

Keywords(s): Antigens, Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Plasmid/Vector, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Recognition of Critical CYP2E1 Epitopes

TITLE: New Diagnostic Test for Drug Induced Liver Injury and Chronic Hepatitis CCASE NUMBER: C10654UNMET NEED Idiosyncratic drug-induced acute liver failure (Id-ALF) is the third most common cause of acute liver failure in the United States and is the leading cause for drug removal from the market. A type of Id-ALF develops in susceptible...

Published: 6/13/2024 | Inventor(s): Dolores Njoku

Keywords(s): Acute Liver Failure, Antigens, Assay, Biologics, Clinical Diagnostics, Disease Indication, Immunotherapy, In Vitro Diagnostics, Liver Disorders, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology > Acute Liver Failure, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Hepatology, Technology Classifications > Research Tools

Recombinant Ehrlichia Phagocytophila AnkA Protein (EPANK1 Protein) From Clone pHGE-D

C03726: Recombinant Ehrlichia Phagocytophila AnkA Protein (EPANK1 Protein) From Clone pHGE-D Technical Details: Recombinant E. phagocytophilia MSP is a major immunodominant protein antigen derived from the human E. phagocytophilia (HE agent) strain BDS. The clone was initially selected based upon reactivity with monoclonal antibody to E. phagocytophilia...

Published: 6/13/2024 | Inventor(s): J. Dumler

Keywords(s): Antigens, Basic Research Biomarker, Cell Signaling, Discovery/Research Tools, Research Reagent

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Research Tools